Phase I Trial of the Combination of Nilotinib and Paclitaxel in Adults With Refractory Solid Tumors

Trial Profile

Phase I Trial of the Combination of Nilotinib and Paclitaxel in Adults With Refractory Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs Nilotinib (Primary) ; Paclitaxel (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 03 Feb 2017 Planned number of patients changed from 24 to 40.
    • 07 Jan 2017 Planned End Date changed from 1 Nov 2016 to 1 Dec 2017.
    • 07 Jan 2017 Planned primary completion date changed from 1 Nov 2016 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top